Autoimmune Diseases – Page 3

IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data

5 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, bispecific antibody T cell, engagers, IGM-2644, Immunoglobulin M, imvotamab, Industry

IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry

Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations

6 months ago talkbio0Tagged Autoimmune Diseases, Biotechnology, biotherapeutics, Candid, Collaboration, engagers, Nona Biosciences, T-Lymphocyte

T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences

Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations

6 months ago talkbio0Tagged Autoimmune Diseases, Biotechnology, Candid, partnerships, R&D, T-Lymphocyte, TCEs

Candid Therapeutics, T-cell engagers (TCEs), autoimmune diseases, R&D collaborations, biotechnology partnerships

AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics

6 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, IL23R gene, Immunology, Inhibitor, Nimble, Peptides, Psoriasis

AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics

Q32 Bio Inc. Faces Market Volatility After Bempikibart Program Update

6 months ago talkbio0Tagged Autoimmune Diseases, bempikibart, Bio Inc., IL-7/TSLP pathways, Market, Performance, Volatility

Q32 Bio Inc., bempikibart, autoimmune diseases, IL-7/TSLP pathways, stock performance, market volatility

Nuvig Therapeutics Secures $161M Series B Financing to Advance Immunomodulatory Portfolio

6 months ago talkbio0Tagged Autoimmune Diseases, Clinical Trials, Immunomodulating Agents, Nuvig, NVG-2089, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Series B financing

Nuvig Therapeutics, Series B financing, immunomodulatory drugs, autoimmune diseases, chronic inflammatory demyelinating polyneuropathy (CIDP), NVG-2089, clinical trials.

Nuvig Therapeutics Secures $161M Series B Funding for Autoimmune Therapy Development

6 months ago talkbio0Tagged Autoimmune Diseases, autoimmune therapy, Immunomodulation, Nuvig, R2B, sanofi

Nuvig Therapeutics, autoimmune therapy, series B funding, Sanofi Ventures, autoimmune diseases, Fc gamma R2B, immunomodulatory therapy

Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases

6 months ago talkbio0Tagged Autoimmune Diseases, Chronic Idiopathic Demyelinating Polyneuropathy, CIDP, Fc Ab fragments, Nuvig, NVG-2089, Phase 2 Clinical Trials, Recombinants, synthetic manufacturing

Nuvig Therapeutics, autoimmune diseases, Phase 2 study, funding, NVG-2089, Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), recombinant Fc Ab fragments, synthetic manufacturing.